Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity-myocarditis and pericarditis-are k...
Saved in:
Main Authors: | Takahiro Niimura (Author), Mitsuhiro Goda (Author), Koji Miyata (Author), Jun Matsumoto (Author), Toshihiko Yoshioka (Author), Hirofumi Hamano (Author), Fuka Aizawa (Author), Kenta Yagi (Author), Yuki Izawa-Ishizawa (Author), Yoshito Zamami (Author), Keisuke Ishizawa (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug-Repositioning Approaches Based on Medical and Life Science Databases
by: Yoshito Zamami, et al.
Published: (2021) -
Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects
by: Hideki Nawa, et al.
Published: (2021) -
Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage
by: Toshihiko Yoshioka, et al.
Published: (2023) -
Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced kidney injury
by: Mitsuhiro Goda, et al.
Published: (2021) -
Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects
by: Hideki Nawa, et al.
Published: (2022)